Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502
   Google Scholar   
Citation:
Blood vol 116 (abstr 331)
Year:
2010
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
Primary
Analysis:
Preliminary
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
Parents:
None
Children:
748  
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                             
Primary Study
CALGB-10502
Secondary Studies:
Phases:
2
Keywords: